#Life_Sciences
Gate2Brain is a Barcelona-based biotech company developing a proprietary peptide-shuttle platform that enables therapies to cross the blood–brain barrier and reach the brain more effectively. Founded as a spin-off from IRB Barcelona, the University of Barcelona, and Sant Joan de Déu Hospital, the company focuses on improving treatment delivery for neurological diseases and pediatric brain cancers. Its lead program, G2B-002, targets aggressive tumors such as DIPG and pediatric glioblastoma and has received Orphan Drug Designation from both the FDA and EMA. Gate2Brain’s technology also has broader applications in CNS disorders and targeted drug delivery.
The Elephants
Involved
Our Role
Inveniam supported the company in winning an EIC Accelerator grant.
We look forward to learning about your innovation.
Cookies are used to access and store information on your device, to offer personalized content and ads based on your data. By choosing “I agree” you consent to Inveniam Group use of cookies. You can refuse or withdraw consent by choosing “Manage Settings”.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)
Clarity is a web analytics service that tracks and reports website traffic.
Service URL: clarity.microsoft.com (opens in a new window)
You can find more information in our Cookies.